These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
175 related articles for article (PubMed ID: 18329876)
41. 1-[3-Aminobenzisoxazol-5'-yl]-3-trifluoromethyl-6-[2'-(3-(R)-hydroxy-N-pyrrolidinyl)methyl-[1,1']-biphen-4-yl]-1,4,5,6-tetrahydropyrazolo-[3,4-c]-pyridin-7-one (BMS-740808) a highly potent, selective, efficacious, and orally bioavailable inhibitor of blood coagulation factor Xa. Pinto DJ; Orwat MJ; Quan ML; Han Q; Galemmo RA; Amparo E; Wells B; Ellis C; He MY; Alexander RS; Rossi KA; Smallwood A; Wong PC; Luettgen JM; Rendina AR; Knabb RM; Mersinger L; Kettner C; Bai S; He K; Wexler RR; Lam PY Bioorg Med Chem Lett; 2006 Aug; 16(15):4141-7. PubMed ID: 16730984 [TBL] [Abstract][Full Text] [Related]
42. Cycloalkanediamine derivatives as novel blood coagulation factor Xa inhibitors. Nagata T; Yoshino T; Haginoya N; Yoshikawa K; Isobe Y; Furugohri T; Kanno H Bioorg Med Chem Lett; 2007 Aug; 17(16):4683-8. PubMed ID: 17555959 [TBL] [Abstract][Full Text] [Related]
43. Factor Xa inhibitors based on a 2-carboxyindole scaffold: SAR of neutral P1 substituents. Nazaré M; Essrich M; Will DW; Matter H; Ritter K; Urmann M; Bauer A; Schreuder H; Dudda A; Czech J; Lorenz M; Laux V; Wehner V Bioorg Med Chem Lett; 2004 Aug; 14(16):4191-5. PubMed ID: 15261268 [TBL] [Abstract][Full Text] [Related]
44. Investigation of the terminal P4 domain in a series of D-phenylglycinamide-based factor Xa inhibitors. Franciskovich JB; Masters JJ; Weber WW; Klimkowski VJ; Chouinard M; Sipes PR; Johnson LM; Snyder DW; Chastain MK; Craft TJ; Towner RD; Gifford-Moore DS; Froelich LL; Smallwood JK; Foster RS; Smith GF; Liebeschuetz JW; Murray CW; Young SC Bioorg Med Chem Lett; 2007 Dec; 17(24):6910-3. PubMed ID: 17976987 [TBL] [Abstract][Full Text] [Related]
45. Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties. Pinto DJ; Galemmo RA; Quan ML; Orwat MJ; Clark C; Li R; Wells B; Woerner F; Alexander RS; Rossi KA; Smallwood A; Wong PC; Luettgen JM; Rendina AR; Knabb RM; He K; Wexler RR; Lam PY Bioorg Med Chem Lett; 2006 Nov; 16(21):5584-9. PubMed ID: 16963264 [TBL] [Abstract][Full Text] [Related]
46. Selective and dual action orally active inhibitors of thrombin and factor Xa. Young RJ; Brown D; Burns-Kurtis CL; Chan C; Convery MA; Hubbard JA; Kelly HA; Pateman AJ; Patikis A; Senger S; Shah GP; Toomey JR; Watson NS; Zhou P Bioorg Med Chem Lett; 2007 May; 17(10):2927-30. PubMed ID: 17420122 [TBL] [Abstract][Full Text] [Related]
47. Ketene aminal-based lactam derivatives as a novel class of orally active FXa inhibitors. Shi Y; Zhang J; Stein PD; Shi M; O'Connor SP; Bisaha SN; Li C; Atwal KS; Bisacchi GS; Sitkoff D; Pudzianowski AT; Liu EC; Hartl KS; Seiler SM; Youssef S; Steinbacher TE; Schumacher WA; Rendina AR; Bozarth JM; Peterson TL; Zhang G; Zahler R Bioorg Med Chem Lett; 2005 Dec; 15(24):5453-8. PubMed ID: 16213711 [TBL] [Abstract][Full Text] [Related]
48. Exploration of potential prodrugs of RWJ-445167, an oxyguanidine-based dual inhibitor of thrombin and factor Xa. Maryanoff BE; McComsey DF; Costanzo MJ; Yabut SC; Lu T; Player MR; Giardino EC; Damiano BP Chem Biol Drug Des; 2006 Jul; 68(1):29-36. PubMed ID: 16923023 [TBL] [Abstract][Full Text] [Related]
49. 1-(2-Naphthyl)-1H-pyrazole-5-carboxylamides as potent factor Xa inhibitors. Part 2: A survey of P4 motifs. Jia ZJ; Wu Y; Huang W; Zhang P; Clizbe LA; Goldman EA; Sinha U; Arfsten AE; Edwards ST; Alphonso M; Hutchaleelaha A; Scarborough RM; Zhu BY Bioorg Med Chem Lett; 2004 Mar; 14(5):1221-7. PubMed ID: 14980670 [TBL] [Abstract][Full Text] [Related]
50. Preparation of 1-(4-methoxyphenyl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective and bioavailable inhibitors of coagulation factor Xa. Fevig JM; Cacciola J; Buriak J; Rossi KA; Knabb RM; Luettgen JM; Wong PC; Bai SA; Wexler RR; Lam PY Bioorg Med Chem Lett; 2006 Jul; 16(14):3755-60. PubMed ID: 16682200 [TBL] [Abstract][Full Text] [Related]
52. Orally active factor Xa inhibitor: synthesis and biological activity of masked amidines as prodrugs of novel 1,4-diazepane derivatives. Koshio H; Hirayama F; Ishihara T; Kaizawa H; Shigenaga T; Taniuchi Y; Sato K; Moritani Y; Iwatsuki Y; Uemura T; Kaku S; Kawasaki T; Matsumoto Y; Sakamoto S; Tsukamoto S Bioorg Med Chem; 2004 Oct; 12(20):5415-26. PubMed ID: 15388168 [TBL] [Abstract][Full Text] [Related]
53. Fluorinated benzyloxyphenyl piperidine-4-carboxamides with dual function against thrombosis: inhibitors of factor Xa and platelet aggregation. de Candia M; Liantonio F; Carotti A; De Cristofaro R; Altomare C J Med Chem; 2009 Feb; 52(4):1018-28. PubMed ID: 19193009 [TBL] [Abstract][Full Text] [Related]
54. Orally active factor Xa inhibitors: investigation of a novel series of 3-amidinophenylsulfonamide derivatives using an amidoxime prodrug strategy. Uchida M; Okazaki K; Mukaiyama H; Isawa H; Kobayashi H; Shiohara H; Muranaka H; Kai Y; Kikuchi N; Takeuchi H; Yokoyama K; Tsuji E; Ozawa T; Hoyano Y; Koizumi T; Misawa K; Hara K; Nakano S; Murakami Y; Okuno H Bioorg Med Chem Lett; 2008 Aug; 18(16):4682-7. PubMed ID: 18667303 [TBL] [Abstract][Full Text] [Related]
55. 7-fluoroindazoles as potent and selective inhibitors of factor Xa. Lee YK; Parks DJ; Lu T; Thieu TV; Markotan T; Pan W; McComsey DF; Milkiewicz KL; Crysler CS; Ninan N; Abad MC; Giardino EC; Maryanoff BE; Damiano BP; Player MR J Med Chem; 2008 Jan; 51(2):282-97. PubMed ID: 18159923 [TBL] [Abstract][Full Text] [Related]
56. Chlorothiophenecarboxamides as P1 surrogates of inhibitors of blood coagulation factor Xa. Mederski WW; Cezanne B; van Amsterdam C; Bühring KU; Dorsch D; Gleitz J; März J; Tsaklakidis C Bioorg Med Chem Lett; 2004 Dec; 14(23):5817-22. PubMed ID: 15501047 [TBL] [Abstract][Full Text] [Related]
57. N-Aryl-gamma-lactams as integrin alphavbeta3 antagonists. Xi N; Arvedson S; Eisenberg S; Han N; Handley M; Huang L; Huang Q; Kiselyov A; Liu Q; Lu Y; Nunez G; Osslund T; Powers D; Tasker AS; Wang L; Xiang T; Xu S; Zhang J; Zhu J; Kendall R; Dominguez C Bioorg Med Chem Lett; 2004 Jun; 14(11):2905-9. PubMed ID: 15125957 [TBL] [Abstract][Full Text] [Related]
58. Design, synthesis, and SAR of cis-1,2-diaminocyclohexane derivatives as potent factor Xa inhibitors. Part II: exploration of 6-6 fused rings as alternative S1 moieties. Yoshikawa K; Kobayashi S; Nakamoto Y; Haginoya N; Komoriya S; Yoshino T; Nagata T; Mochizuki A; Watanabe K; Suzuki M; Kanno H; Ohta T Bioorg Med Chem; 2009 Dec; 17(24):8221-33. PubMed ID: 19900814 [TBL] [Abstract][Full Text] [Related]
59. Intermolecular interactions and characterization of the novel factor Xa exosite involved in macromolecular recognition and inhibition: crystal structure of human Gla-domainless factor Xa complexed with the anticoagulant protein NAPc2 from the hematophagous nematode Ancylostoma caninum. Murakami MT; Rios-Steiner J; Weaver SE; Tulinsky A; Geiger JH; Arni RK J Mol Biol; 2007 Feb; 366(2):602-10. PubMed ID: 17173931 [TBL] [Abstract][Full Text] [Related]
60. Preparation of L-proline based aeruginosin 298-A analogs: optimization of the P1-moiety. Wang G; Goyal N; Hopkinson B Bioorg Med Chem Lett; 2009 Jul; 19(14):3798-803. PubMed ID: 19447619 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]